Autoantibodies against tumor-related antigens: incidence and biologic significance.
Standard
Autoantibodies against tumor-related antigens: incidence and biologic significance. / Kobold, Sebastian; Luetkens, Tim; Cao, Yanran; Bokemeyer, Carsten; Atanackovic, Djordje.
In: HUM IMMUNOL, Vol. 71, No. 7, 7, 2010, p. 643-651.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Autoantibodies against tumor-related antigens: incidence and biologic significance.
AU - Kobold, Sebastian
AU - Luetkens, Tim
AU - Cao, Yanran
AU - Bokemeyer, Carsten
AU - Atanackovic, Djordje
PY - 2010
Y1 - 2010
N2 - In the last two decades, tumors have been found to evoke antigen-specific immune responses. However, the biologic role of spontaneous tumor-specific T-cell and antibody responses are still a matter of controversy. Paradoxically, cancer-related immunity has been suggested to promote tumor growth, to effectively suppress tumor progression, or to simply represent a clinically irrelevant epiphenomenon. In recent years, research has focused on tumor antigen-specific T cells, and little has been done to systematically evaluate the significance of spontaneously occurring tumor-associated autoantibodies. For this article, we screened the relevant literature on the incidence and significance of tumor-induced antibodies. We found that such spontaneous autoantibodies, targeting different antigens, are present at varying frequencies throughout a wide diversity of malignancies. In particular entities, these antibodies are already used or might be developed into diagnostic tools. Furthermore, autologous antibodies against some antigen families have a prognostic significance. Finally, tumor antigen-specific autoantibodies seem to be capable of disrupting tumor growth but, in certain instances, are also misused by the malignancy to evade immune control.
AB - In the last two decades, tumors have been found to evoke antigen-specific immune responses. However, the biologic role of spontaneous tumor-specific T-cell and antibody responses are still a matter of controversy. Paradoxically, cancer-related immunity has been suggested to promote tumor growth, to effectively suppress tumor progression, or to simply represent a clinically irrelevant epiphenomenon. In recent years, research has focused on tumor antigen-specific T cells, and little has been done to systematically evaluate the significance of spontaneously occurring tumor-associated autoantibodies. For this article, we screened the relevant literature on the incidence and significance of tumor-induced antibodies. We found that such spontaneous autoantibodies, targeting different antigens, are present at varying frequencies throughout a wide diversity of malignancies. In particular entities, these antibodies are already used or might be developed into diagnostic tools. Furthermore, autologous antibodies against some antigen families have a prognostic significance. Finally, tumor antigen-specific autoantibodies seem to be capable of disrupting tumor growth but, in certain instances, are also misused by the malignancy to evade immune control.
M3 - SCORING: Zeitschriftenaufsatz
VL - 71
SP - 643
EP - 651
JO - HUM IMMUNOL
JF - HUM IMMUNOL
SN - 0198-8859
IS - 7
M1 - 7
ER -
